MedTrace Logo

Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

NCT03467360 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-01-20

No results posted yet for this study

Summary

The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to:

1. The over-expression of carbonic anhydrases in this type of cancer,
2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines,
3. The observed synergy between irradiation and inhibition of carbonic anhydrases,
4. Potential anti-tumor immune effect caused by decreased extracellular acidity.

Conditions

Interventions

DRUG

acetazolamide in combination with platinum and etoposide-based radiochemotherapy

Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).

DRUG

acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC

acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC

Sponsors & Collaborators

  • Centre Antoine Lacassagne

    lead OTHER

Principal Investigators

  • Vanessa VIDAL · Centre Antoine Lacassagne

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-02
Primary Completion
2026-10-27
Completion
2027-04-27

Countries

  • France
  • Monaco

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467360 on ClinicalTrials.gov